



**Recipient Information**

**1. Recipient Name**

Missouri Department of Health  
920 Wildwood Dr  
Jefferson City, MO 65109-5796  
[NO DATA]

**2. Congressional District of Recipient**

03

**3. Payment System Identifier (ID)**

[REDACTED]

**4. Employer Identification Number (EIN)**

[REDACTED]

**5. Data Universal Numbering System (DUNS)**

878092600

**6. Recipient's Unique Entity Identifier**

**7. Project Director or Principal Investigator**

Mrs. Cheryl L Kerr  
Public Health Program Supervisor  
cheryl.kerr@health.mo.gov  
5737516476

**8. Authorized Official**

Mrs. Marcia Mahaney  
Director, Division of Administration  
marcia.mahaney@health.mo.gov  
573-751-6014

**Federal Agency Information**

CDC Office of Financial Resources

**9. Awarding Agency Contact Information**

Kim McDowell  
Grant Management Specialist  
qpx9@cdc.gov  
404-498-4105

**10. Program Official Contact Information**

Ashley Trehame  
Health Scientist  
qmp4@cdc.gov  
404-718-1434

**Federal Award Information**

**11. Award Number**

5 NU50CK000546-03-00

**12. Unique Federal Award Identification Number (FAIN)**

NU50CK000546

**13. Statutory Authority**

301(A)AND317(K)(2)PHS42USC241(A)247B(K)2

**14. Federal Award Project Title**

CK19-1904 Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC)

**15. Assistance Listing Number**

93.323

**16. Assistance Listing Program Title**

Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)

**17. Award Action Type**

Non-Competing Continuation

**18. Is the Award R&D?**

No

**Summary Federal Award Financial Information**

|  |            |                   |                |
|--|------------|-------------------|----------------|
| <b>19. Budget Period Start Date</b>  | 08/01/2021 | <b>- End Date</b> | 07/31/2022     |
| <b>20. Total Amount of Federal Funds Obligated by this Action</b>  |            |                   | \$1,908,751.00 |
| 20a. Direct Cost Amount  |            |                   | \$1,670,969.00 |
| 20b. Indirect Cost Amount  |            |                   | \$237,782.00   |
| <b>21. Authorized Carryover</b>  |            |                   | \$0.00         |
| <b>22. Offset</b>  |            |                   | \$0.00         |
| <b>23. Total Amount of Federal Funds Obligated this budget period</b>  |            |                   | \$0.00         |
| <b>24. Total Approved Cost Sharing or Matching, where applicable</b>   |            |                   | \$0.00         |
| <b>25. Total Federal and Non-Federal Approved this Budget Period</b>   |            |                   | \$1,908,751.00 |
| <b>26. Project Period Start Date</b>   | 08/01/2019 | <b>- End Date</b> | 07/31/2024     |
| <b>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</b> |            |                   | Not Available  |

**28. Authorized Treatment of Program Income**

ADDITIONAL COSTS

**29. Grants Management Officer - Signature**

Ms. Freda Johnson  
Grants Management Officer

**30. Remarks**

For COVID document number '-BLDRC4' recipients will not be required to submit monthly financial reporting.



| Recipient Information   |
|---|
| <b>Recipient Name</b><br>Missouri Department of Health<br>920 Wildwood Dr<br>Jefferson City, MO 65109-5796<br>[NO DATA] |
| <b>Congressional District of Recipient</b><br>03  |
| <b>Payment Account Number and Type</b><br>[REDACTED]  |
| <b>Employer Identification Number (EIN) Data</b><br>[REDACTED]  |
| <b>Universal Numbering System (DUNS)</b><br>878092600   |
| <b>Recipient's Unique Entity Identifier</b><br>Not Available  |
| <b>31. Assistance Type</b><br>Cooperative Agreement   |
| <b>32. Type of Award</b><br>Demonstration   |

| 33. Approved Budget<br>(Excludes Direct Assistance)                                 |                       |
|---|-----------------------|
| I. Financial Assistance from the Federal Awarding Agency Only                       |                       |
| II. Total project costs including grant funds and all other financial participation |                       |
| a. Salaries and Wages   | \$781,957.00          |
| b. Fringe Benefits  | \$469,521.00          |
| c. Total Personnel Costs  | \$1,251,478.00        |
| d. Equipment  | \$0.00                |
| e. Supplies   | \$198,982.00          |
| f. Travel   | \$36,704.00           |
| g. Construction   | \$0.00                |
| h. Other  | \$81,234.00           |
| i. Contractual  | \$102,571.00          |
| <b>j. TOTAL DIRECT COSTS</b>  | <b>\$1,670,969.00</b> |
| <b>k. INDIRECT COSTS</b>  | <b>\$237,782.00</b>   |
| <b>l. TOTAL APPROVED BUDGET</b>   | <b>\$1,908,751.00</b> |
| <b>m. Federal Share</b>   | <b>\$1,908,751.00</b> |
| <b>n. Non-Federal Share</b>   | <b>\$0.00</b>         |

**34. Accounting Classification Codes**

| FY-ACCOUNT NO. | DOCUMENT NO.         | ADMINISTRATIVE CODE | OBJECT CLASS | AMT ACTION FINANCIAL ASSISTANCE | APPROPRIATION |
|----------------|----------------------|---------------------|--------------|---------------------------------|---------------|
| 1-921047Q      | 19NU50CK000546HISC3  | CK                  | 41 51        | \$51,441 00                     | 75-2024-0943  |
| 1-9211175      | 19NU50CK000546       | CK                  | 41 51        | \$166,437 00                    | 75-21-0949    |
| 1-939014P      | 19NU50CK000546       | CK                  | 41 51        | \$57,349 00                     | 75-21-0949    |
| 1-93901FT      | 19NU50CK000546       | CK                  | 41 51        | \$51,441 00                     | 75-21-0959    |
| 1-93904SH      | 19NU50CK000546       | CK                  | 41 51        | \$61,729 00                     | 75-21-0959    |
| 1-93905VH      | 19NU50CK000546       | CK                  | 41 51        | \$143,561 00                    | 75-21-0949    |
| 1-93906EZ      | 19NU50CK000546       | CK                  | 41 51        | \$10,507 00                     | 75-21-0947    |
| 1-93908MV      | 19NU50CK000546       | CK                  | 41 51        | \$317,667 00                    | 75-21-0949    |
| 1-93909PE      | 19NU50CK000546       | CK                  | 41 51        | \$21,772 00                     | 75-X-0951     |
| 1-9390ASV      | 19NU50CK000546       | CK                  | 41 51        | \$132,236 00                    | 75-21-0951    |
| 1-9390EWQ      | 19NU50CK000546JKOWC3 | CK                  | 41 51        | \$190,649 00                    | 75-2024-0943  |
| 1-9390G74      | 19NU50CK000546       | CK                  | 41 51        | \$124,388 00                    | 75-X-0951     |
| 1-9390GDG      | 19NU50CK000546       | CK                  | 41 51        | \$341,225 00                    | 75-X-0949     |
| 1-9390GL9      | 19NU50CK000546BLDRC4 | CK                  | 41 51        | \$4,579 00                      | 75-X-0943     |
| 1-9390H4A      | 19NU50CK000546       | CK                  | 41 51        | \$26,969 00                     | 75-21-0949    |
| 1-939ZRQB      | 19NU50CK000546       | CK                  | 41 51        | \$16,000 00                     | 75-21-0950    |
| 1-939ZVJC      | 19NU50CK000546       | CK                  | 41 51        | \$190,801 00                    | 75-21-0949    |



**DEPARTMENT OF HEALTH AND HUMAN SERVICES** Notice of Award

Centers for Disease Control and Prevention

Award# 5 NU50CK000546-03-00

FAIN# NU50CK000546

Federal Award Date: 06/29/2021

**Direct Assistance**

| BUDGET CATEGORIES | PREVIOUS AMOUNT (A) | AMOUNT THIS ACTION (B) | TOTAL (A + B) |
|-------------------|---------------------|------------------------|---------------|
| Personnel         | \$0.00              | \$0.00                 | \$0.00        |
| Fringe Benefits   | \$0.00              | \$0.00                 | \$0.00        |
| Travel            | \$0.00              | \$0.00                 | \$0.00        |
| Equipment         | \$0.00              | \$0.00                 | \$0.00        |
| Supplies          | \$0.00              | \$0.00                 | \$0.00        |
| Contractual       | \$0.00              | \$0.00                 | \$0.00        |
| Construction      | \$0.00              | \$0.00                 | \$0.00        |
| Other             | \$0.00              | \$0.00                 | \$0.00        |
| Total             | \$0.00              | \$0.00                 | \$0.00        |

# AWARD ATTACHMENTS

Missouri Department of Health

5 NU50CK000546-03-00

---

1. Terms and Conditions- Continuation

## AWARD INFORMATION

**Incorporation:** In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at

<https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CK19-1904, titled *Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC)*, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

**Approved Funding:** Funding in the amount of \$1,908,751 is approved for the Year 03 budget period, which is August 1, 2021 through July 31, 2022. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third-party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

The NOFO provides for the funding of multiple components under this award. The approved component funding levels for this notice of award are:

| Funded Component   | Amount      | Suffix Document Number in PMS |
|--------------------|-------------|-------------------------------|
| CORE FUNDING       | \$1,666,661 | None                          |
| Project C1: HIS    | \$51,441    | HISC3                         |
| Project W: SET-NET | \$190,649   | JKOWC3                        |

**Coronavirus Disease 2019 (COVID-19) Funds:** A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139); the Consolidated Appropriations Act and the Coronavirus Response and Relief Supplement Appropriations Act, 2021 (P.L. 116-260) and/or the American Rescue Plan of 2021 [P.L. 117-2] agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS-

CoV-2 or to diagnose a possible case of COVID-19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC. HHS laboratory reporting guidance is posted at: <https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf>.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

**Financial Assistance Mechanism:** Cooperative Agreement

**Substantial Involvement by CDC:** This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

- National coordination of activities where appropriate.
- Targeted Electronic Data Exchange (EDX) technical assistance to public health departments and public health labs.

**Administrative Requirement:** Within 30 days of award issuance, the recipient must submit the ELC Excel budget workbook with all requests for additional details in the 'CDC Program Notes' addressed. Those 'CDC Program Notes' that only provide additional programmatic guidance do not require recipient response. The submission must be done as a Grant Note in GrantSolutions.

**Expanded Authority:** The recipient is permitted the following expanded authority in the administration of the award.

- Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of unobligated funds in Section 12 "Remarks" of the annual Federal Financial Report. If the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient's authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of these actions.

**Program Income:** Any program income generated under this grant or cooperative agreement will be used in accordance with the Addition alternative.

**Addition alternative:** Under this alternative, program income is added to the funds committed to

the project/program and is used to further eligible project/program objectives.

#### FUNDING RESTRICTIONS AND LIMITATIONS

**Indirect Costs:** Indirect costs are approved based on the negotiated indirect cost rate agreement dated April 12, 2021, which calculates indirect costs as follows, a Predetermined is approved at a rate of 19% of the base, which includes, direct salaries and wages including all fringe benefits. The effective dates of this indirect cost rate are from July 1, 2021 to June 30, 2022.

#### REPORTING REQUIREMENTS

##### **Financial Reporting Requirement:**

##### **COVID-19:**

- Monthly fiscal reports (beginning 30 days after NOAs are issued)

##### **Additional Reporting Requirements:**

- Quarterly progress reports on status of timelines, goals, and objectives as defined by CDC in approved work plans
- Quarterly Performance measure data
- CDC may require recipients to develop annual progress reports (APRs). CDC will provide APR guidance and optional templates should they be required

**Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS):** Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services  
Kim McDowell, Grants Management Specialist  
Centers for Disease Control and Prevention  
Branch 1  
2939 Flowers Road, MS-TV-2  
Atlanta, GA 30341  
Email: QPX9@CDC.GOV (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services  
Office of the Inspector General  
ATTN: Mandatory Grant Disclosures, Intake Coordinator  
330 Independence Avenue, SW  
Cohen Building, Room 5527  
Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or  
Email: [MandatoryGranteeDisclosures@oig.hhs.gov](mailto:MandatoryGranteeDisclosures@oig.hhs.gov)

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

#### PAYMENT INFORMATION

*The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to [hhstips@oig.hhs.gov](mailto:hhstips@oig.hhs.gov) or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.*

**Payment Management System Subaccount:** Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 2 of the Notice of Award must be known in order to draw down funds.

#### CDC Staff Contacts

**Grants Management Specialist:** The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

**Program/Project Officer:** The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

**Grants Management Officer:** The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of



the recipient organization.